Sign In
Buy NVO
$47.41
-0.0100 (-0.0211%)
At Close: Jun 24, 2026
The FDA has approved the first GLP-1 pill for weight loss, clearing a tablet from Novo Nordisk
06:05pm, Monday, 22'nd Dec 2025
Novo Nordisk said it plans to start selling the new pill in the U.S. soon after the new year, with a cash price of $149 a month for the starting dose.
Novo Nordisk wins US approval for weight-loss pill
05:59pm, Monday, 22'nd Dec 2025
The U.S. Food and Drug Administration approved Novo Nordisk's weight-loss pill on Monday, giving the Danish drugmaker a leg up in the race to market a potent oral medication for shedding pounds as it
Xmas stock picks wrap-up: who won the 2025 competition?
07:01am, Monday, 22'nd Dec 2025
Traditions are a core part of the Christmas experience and, for this Proactive Investors journalist, one of these is the annual stock-picking competition. A...
Novo Nordisk A/S $NVO Shares Sold by Baldwin Wealth Partners LLC MA
03:26am, Monday, 22'nd Dec 2025
Baldwin Wealth Partners LLC MA lessened its holdings in Novo Nordisk A/S (NYSE: NVO) by 82.0% during the undefined quarter, according to its most recent disclosure with the Securities and Exchange Com
Novo Nordisk (NYSE: NVO) Stock Price Prediction and Forecast 2026-2030 (Dec 2025)
08:25am, Sunday, 21'st Dec 2025
Among all the weight loss drugs, Ozempic has become a phenomenon. With as much as $17 billion in sales in 2024 and over $14 billion in the first nine months of 2025, it shows no signs of slowing down,
Benzinga Bulls And Bears: Carnival, Caterpillar, Meta — And Markets Make Modest Gains
08:31am, Saturday, 20'th Dec 2025
Benzinga examined the prospects for many investors' favorite stocks over the last week - here's a look at some of our top stories.
These 5 Stocks Are Set To Dominate 2026
12:49pm, Friday, 19'th Dec 2025
My 2025 picks outperformed the S&P 500 by 9.4% and Nasdaq 100 by 5.9%, validating my growth-value approach. Each stock on this list is operating in a different market segment and two are based in Euro
Trump to announce new drug-pricing deals later today
10:45am, Friday, 19'th Dec 2025
The White House is getting ready to announce more deals with drugmakers aimed at lowering drug prices.
Novo Nordisk Files NDA for Next-Generation Obesity Drug CagriSema
10:01am, Friday, 19'th Dec 2025
NVO files an NDA with the FDA for once-weekly CagriSema, a combo obesity injection showing superior weight loss in obese patients in phase III studies.
Novo Nordisk: Oral Wegovy, Supply Chain, And Restructuring = Big Upside Ahead
08:00am, Friday, 19'th Dec 2025
Novo Nordisk offers compelling value, trading at a 32% discount to fair value with a 3.6% yield and robust dividend growth. NVO's semaglutide-based drugs drive 74% of sales, but pipeline innovation, c
Prediction: 1 Healthcare Giant Set to Soar in 2026
09:00pm, Thursday, 18'th Dec 2025
Novo Nordisk cut its guidance and changed its CEO this past year. Amid the troubling developments, the stock has nose-dived more than 40%.
Market Today: CPI Cools; Micron Lifts AI Stocks (MU)
05:35pm, Thursday, 18'th Dec 2025
Guru Stock PicksCI Select Canadian Equity Fund has made the following transactions:Reduce in TSX: ABX by 9.95%Sold out in TSX:DOLAdd in TSX: KEY by 27.62%New posi
Major stock indexes surged Thursday after delayed Consumer Price Index data came in better than expected, with the blue-chip Dow Jones Industrial Average and benchmark S&P 500 poised to end four-sessi
Can Higher-Dose Wegovy Help Novo Nordisk Regain Obesity Market Share?
10:56am, Thursday, 18'th Dec 2025
NVO seeks approval for a 7.2 mg Wegovy dose after study data showed stronger weight loss that can challenge Zepbound's U.S. momentum.
Wegovy Maker Novo Nordisk Files For FDA Approval of Obesity Drug CagriSema
09:09am, Thursday, 18'th Dec 2025
Wegovy maker Novo Nordisk filed for U.S. FDA approval of CagriSema, a once-weekly shot that combines two compounds to treat obesity.
